Lars Fruergaard Jørgensen, Novo Nordisk CEO (EUBIO21)

No­vo Nordisk to make all dos­es of its weight loss drug avail­able in the US by end of the year

With pro­duc­tion fi­nal­ly up and run­ning for its weight loss drug We­govy, No­vo Nordisk said on Wednes­day that it plans to make all dose strengths avail­able in the US by the end of the year.

How­ev­er, CEO Lars Fruer­gaard Jør­gensen al­so not­ed “a bit low­er ramp-up ver­sus planned,” as the com­pa­ny’s stock $NVO plum­met­ed more than 12% on Wednes­day. Shares were back up 4.6% on Thurs­day, pric­ing in at around $104.54 apiece.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.